Devil genome sequenced: Hope for endangered Tasmanian Devils

Tasmanian Devil Salem died at age seven but made a difference to her endangered species. Only 50 micrograms of her tissue was taken and processed by Australian genetic scientist Elizabeth Murchison, using new US technology, to produce the first devil genome sequence. As a result, the fight against devil facial tumor disease now has a draft DNA reference map. This was presented at a genetic conference in Hobart yesterday.

Dr Murchison, of the Sanger Institute in Cambridge, England said, “This is really a prerequisite for understanding the genetics of this cancer…We now have a usable reference genome so we can look at its mutations.” The facial tumor is believed to have arisen as a mutation in an individual devil about 20 years ago. Then this always fatal cancer spread to more than three-quarters of the devils' range in Tasmania. In five years it could cover the whole range, according to Menna Jones, scientific adviser to the state government's Save the Tasmanian Devil program. She said at a public meeting in Hobart, “We only have about 30,000 individuals left to run this race.”

Now with the genome sequenced, Dr Murchison said, devil researchers could follow the geographic travels of the cancer. She said, “By comparing our draft sequence with samples taken from many hundreds of devils suffering from this cancer, we can begin to look at the spread of the disease quite literally…We will be able to identify any variants and mutations as it has moved through the population of devils.”

At present under a national conservation program, dozens of devils are being bred by zoos. Isolation of healthy devils is the only hope. Dr Murchison said that by identifying mutations it might also be possible one day to treat the disease with drugs. The reference genome was sequenced in eight days using a machine developed by Californian company Illumina. Dr Murchison was working with the Cancer Genome Project at the UK's Wellcome Trust Sanger Institute.

Sanger Institute director and Cancer Genome Project joint head Mike Stratton said the sequence was more than a boon to efforts to protect the devil. “We believe this research will also teach us important lessons about the evolution of cancers…We are actually peering into the very same cancer that originated in just one devil some 20 years ago, a cancer that has long survived its original host…In research terms this is truly unique. It will provide an unprecedented window into the evolution of cancer,” he said.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). Devil genome sequenced: Hope for endangered Tasmanian Devils. News-Medical. Retrieved on November 28, 2024 from https://www.news-medical.net/news/20100916/Devil-genome-sequenced-Hope-for-endangered-Tasmanian-Devils.aspx.

  • MLA

    Mandal, Ananya. "Devil genome sequenced: Hope for endangered Tasmanian Devils". News-Medical. 28 November 2024. <https://www.news-medical.net/news/20100916/Devil-genome-sequenced-Hope-for-endangered-Tasmanian-Devils.aspx>.

  • Chicago

    Mandal, Ananya. "Devil genome sequenced: Hope for endangered Tasmanian Devils". News-Medical. https://www.news-medical.net/news/20100916/Devil-genome-sequenced-Hope-for-endangered-Tasmanian-Devils.aspx. (accessed November 28, 2024).

  • Harvard

    Mandal, Ananya. 2018. Devil genome sequenced: Hope for endangered Tasmanian Devils. News-Medical, viewed 28 November 2024, https://www.news-medical.net/news/20100916/Devil-genome-sequenced-Hope-for-endangered-Tasmanian-Devils.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists decode ovarian aging with groundbreaking molecular atlas